Clinical trial
A Safety and Efficacy Study of Infliximab (Remicade) in Patients With Moderate…
NCT00207662 · Centocor, Inc., Industry · Completed
Key facts
| NCT number | NCT00207662 |
|---|---|
| Title | A Safety and Efficacy Study of Infliximab (Remicade) in Patients With Moderate to Severe Active Crohn's Disease |
| Official title | ACCENT I - A Randomized, Double-blind, Placebo-controlled Trial of Anti-TNFa Chimeric Monoclonal Antibody (Infliximab, Remicade) in the Long-term Treatment of Patients With Moderately to Severely Active Crohn's Disease |
| Lead sponsor | Centocor, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Crohn Disease |
| Intervention type | Drug |
| Interventions | infliximab or placebo |
| Enrollment | 580 |
| Start date | Jul 1, 2000 |
| Completion | Nov 1, 2005 |
| First posted | Sep 21, 2005 |
| Last update posted | Apr 27, 2010 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: